DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implications
University of British Columbia · Ono Pharmaceutical (United States) · +1 more institution
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
132
total citations
- FWCI
- 33.26
- Percentile
- 100%
- References
- 203
Citations per year
Authors
3Topics & keywords
Topics
Keywords
- DNA damage
- Genome instability
- DNA repair
- PARP inhibitor
- Homologous recombination
- Cancer research
- Poly ADP ribose polymerase
- Clinical trial
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.